A new start: Learn, Grow and Thrive at iBHE, Tsinghua SIGS
SHENZHEN, China, Nov. 28, 2022 /PRNewswire/ -- Keer HU, enrolled in the Bioengineering and Translational Medicine program at the Institute of Biopharmaceutical and Health Engineering(iBHE), Tsinghua Shenzhen International Graduate School (SIGS), is a freshman in the class of 2022. Also working on many projects as a young designer, she has won many awards and exhibition invitations at home and...
TELEHEALTH USAGE IN ASIA PACIFIC FOR PEOPLE LIVING WITH HIV INCREASING, BUT DATA PRIVACY AND LACK OF PERSONAL CONTACT STILL SEEN AS A BARRIER TO WIDER USE
- Half of the people living with HIV (PLHIV) and individuals at-risk (IARs) surveyed in the region increased their usage of telehealth services over the past year; this is driven by the availability of new telehealth services during pandemic - Top factor impacting usage of telehealth services for PLHIV is...
Nuance Pharma announces partnership with DKSH to launch Bentrio™ Nasal Spray in Hong Kong and Macau
SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces partnership with DKSH Hong Kong (DKSH HK) Business Unit Healthcare to launch BentrioTM nasal spray in Hong Kong and Macau, marking the very first milestone of Nuance Pharma's commercial expansion in the APAC market. Under the cooperation agreement, DKSH HK will provide full-agency services including key account management, marketing...
Yidu Tech Announces Results for the First Half of FY2023: Adjusted Net Loss Narrowed down 30.3% YoY, Strategic Focus Enhanced Business Resilience
HONG KONG, Nov. 28, 2022 /PRNewswire/ -- Yidu Tech Inc. ("Yidu Tech" or "the Company", together with its subsidiaries and consolidated affiliated entities, "the Group", HKEx: 2158), a leading corporate in China's healthcare intelligence industry, announced the interim results for the six months ended 30 September 2022 ("the first half of FY2023" or "the Reporting Period"). Despite the challenging and uncertain external...
Peptron’s PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda’s Leuplin
Peptron's PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda's Leuplin. Global and regional deal to be initiated. PT105 represents Korea's first commercialized generic drug of Leuplin, applied with SmartDepot technology. Development of 3- and 6-month generic Leuprolide for the global market soon to be initiated. DAEJEON, South Korea,...
Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy
-- Taiwan Food and Drug Administration grants Accelerated Approval Designation (AAD) to Nefecon -- -- Ministry of Food and Drug Safety in South Korea grants ODD to Nefecon -- -- Nefecon is a first-in-disease treatment for IgAN patients and has been approved in U.S. and E.U. -- SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical...
Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings
ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, today announced that clinical data from multiple trials in relation to TYVYT® (sintilimab injection), olverembatinib (BCL-ABL TIK), IBI188(anti-CD47 monoclonal antibody),...
Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients
LVGN7409 is a next generation CD40 agonistic antibody; Nivolumab is a PD-1 checkpoint inhibitor; docetaxel is an anti-tubulin chemotherapy agent Combination study to begin in 1st half 2023 SHANGHAI and SUZHOU, China, Nov. 28, 2022 /PRNewswire/ -- Lyvgen Biopharma, a leading innovative global biotech company dedicated to discovering, developing and commercializing...
Fovia Ai to Showcase AI Visualization Integrations at IAIP Exhibit, RSNA 2022
Fovia Ai Provides Efficiency Gains for Radiology Workflows CHICAGO, Nov. 27, 2022 /PRNewswire/ -- Fovia Ai, Inc., a subsidiary of Fovia, Inc., a world leader in advanced visualization for nearly two decades and a preeminent provider of zero-footprint, cloud-based imaging SDKs, today announced that it will be showcasing AI visualization, navigation and seamless integrations of AI that provide...
New study on deep learning technology for improving MRI image quality published in European Radiology
SwiftMR™, an AI-powered MRI reconstruction solution from AIRS Medical proved its performance for enhancing the image quality of 3D high-resolution MRI SEOUL, South Korea, Nov. 25, 2022 /PRNewswire/ -- A recent study published in European Radiology demonstrated that SwiftMR, an AI-powered MRI reconstruction solution from AIRS Medical, successfully denoises 3D MR images and improves its image quality by using routine clinical...
